Your browser doesn't support javascript.
loading
A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.
Jarskog, L Fredrik; Lowy, Martin T; Grove, Richard A; Keefe, Richard S E; Horrigan, Joseph P; Ball, M Patricia; Breier, Alan; Buchanan, Robert W; Carter, Cameron S; Csernansky, John G; Goff, Donald C; Green, Michael F; Kantrowitz, Joshua T; Keshavan, Matcheri S; Laurelle, Marc; Lieberman, Jeffrey A; Marder, Stephen R; Maruff, Paul; McMahon, Robert P; Seidman, Larry J; Peykamian, Margaret A.
Affiliation
  • Jarskog LF; University of North Carolina School of Medicine, Chapel Hill, NC, United States.
  • Lowy MT; GlaxoSmithKline Neurosciences Therapy Area Unit, RTP, NC, United States.
  • Grove RA; GlaxoSmithKline Neurosciences Clinical Statistics, Stockley Park, UK. Electronic address: Richard.a.grove@gsk.com.
  • Keefe RS; Duke University Medical Center, Durham, NC, United States.
  • Horrigan JP; GlaxoSmithKline Neurosciences Therapy Area Unit, RTP, NC, United States.
  • Ball MP; Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, United States.
  • Breier A; Indiana University School of Medicine, Indianapolis, IN, United States.
  • Buchanan RW; Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, United States.
  • Carter CS; University of California, Davis, CA, United States.
  • Csernansky JG; Feinberg School of Medicine, Chicago, IL, United States.
  • Goff DC; Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, United States.
  • Green MF; University of California, Los Angeles, CA, United States.
  • Kantrowitz JT; New York State Psychiatric Institute, New York , NY, United States.
  • Keshavan MS; Harvard Medical School, Boston, MA, United States.
  • Laurelle M; GlaxoSmithKline Neuroscience CEDD, Harlow, UK.
  • Lieberman JA; New York State Psychiatric Institute, New York , NY, United States; Columbia University, New York, NY, United States.
  • Marder SR; University of California, Los Angeles, CA, United States.
  • Maruff P; Cogstate, Sydney, Australia.
  • McMahon RP; Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, United States.
  • Seidman LJ; Harvard Medical School, Boston, MA, United States.
  • Peykamian MA; GlaxoSmithKline Neurosciences Therapy Area Unit, RTP, NC, United States.
Schizophr Res ; 164(1-3): 136-42, 2015 May.
Article in En | MEDLINE | ID: mdl-25728831
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia / Benzazepines / Cognition Disorders / Histamine Antagonists Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Schizophr Res Journal subject: PSIQUIATRIA Year: 2015 Document type: Article Affiliation country: United States Country of publication: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia / Benzazepines / Cognition Disorders / Histamine Antagonists Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Schizophr Res Journal subject: PSIQUIATRIA Year: 2015 Document type: Article Affiliation country: United States Country of publication: Netherlands